Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over period, even as revenues growth remained stagnant. The company’ stock jumped over 4% during pre-market hours.
Adjusted net profit for the second quarter came in at 12 cents per share, which was higher than the Wall Street estimate of 7 cents per share.
Revenues edged down almost 1% from last year and came in at $5.37 billion. This missed the analysts’ projection of $5.41 billion.
In the Retail Pharmacy segment, revenues edged down 1.6% hurt by store closures, even though same-store sales modestly increased 0.4%. Pharmacy sales have been negatively impacted by new generic introductions.
Front-end same-store sales, excluding cigarettes and tobacco products, decreased 0.6% year-over-year.
Outlook
Looking ahead, the company expects net sales to be in the range of $21.5 billion to $21.9 billion in fiscal 2020 and annual same-store sales growth in the range of 0-1%. Adjusted EPS is expected to be between $0.00 and $0.56.
RAD stock has declined 70% in the last one year, and 52% in the year-to-date period. The company’s inability to stop its stock from free fall culminated in CEO John Standley stepping down from the top post last month.
The newly appointed CEO Heyward Donigan has vast experience in the healthcare industry and is on Fortune’s watch list of executives who have the potential to become the world’s most powerful women.
Following failed merger bids with Walgreens (NASDAQ: WBA) and more recently Albertsons, the company is now looking up at the new CEO to save the sinking ship. The stock has slightly recovered since the appointment of Donigan.
Donigan said in a statement after the earnings announcement, “Our Adjusted EBITDA results exceeded our plan driven by prescription count growth and strong expense control. This gives us important momentum for our future, and I look forward to working closely with our team to deliver a solid finish to our fiscal year and position Rite Aid as an innovative leader in our industry.”
Most Popular
SBUX Earnings: Key quarterly highlights from Starbucks’ Q4 2024 financial results
Starbucks Corporation (NASDAQ: SBUX) reported its fourth quarter 2024 earnings results today. Consolidated net revenues declined 3%, including on a constant currency basis, to $9.1 billion compared to the same
Key highlights from Biogen’s (BIIB) Q3 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its third quarter 2024 earnings results today. Total revenue decreased 3% year-over-year to $2.46 billion. Revenues were down 3% on a constant currency basis as
Infographic: Caterpillar (CAT) reports lower Q3 revenue and adj. profit
Caterpillar Inc. (NYSE: CAT), a leading manufacturer of construction and mining equipment, on Wednesday reported a decrease in revenue and adjusted earnings for the third quarter of 2024. Sales and
Comments
Comments are closed.